Background: Mepolizumab (MEP) is the first anti Interleukin (IL)-5 add-on therapy approved for the treatment of severe refractory eosinophilic asthma. Case presentation: We describe here the case of a 49 years-old woman with Aspirin-exacerbated respiratory disease (AERD), chronic rhinosinusitis, nasal polyposis and eosinophilic gastroenteritis successfully treated with MEP. Several laboratory and clinical items improved during therapy; moreover MEP showed to be useful as steroid sparing agent. Conclusions: This case supports that the use of mepolizumab can be effective also in other eosinophilic conditions different from asthma and this opens to new therapeutic perspectives.
Caruso, C., Colantuono, S., Pugliese, D., Di Mario, C., Tolusso, B., Gremese, E., Papparella, L. G., Castri, F., Gasbarrini, A., Romano, A., Armuzzi, A., Severe eosinophilic asthma and aspirin-exacerbated respiratory disease associated to eosinophilic gastroenteritis treated with mepolizumab: A case report, <<ALLERGY, ASTHMA, AND CLINICAL IMMUNOLOGY>>, N/A; 16 (1): N/A-N/A. [doi:10.1186/s13223-020-00423-3] [http://hdl.handle.net/10807/205646]
Severe eosinophilic asthma and aspirin-exacerbated respiratory disease associated to eosinophilic gastroenteritis treated with mepolizumab: A case report
Caruso, Cristiano;Pugliese, Daniela;Di Mario, Clara;Tolusso, Barbara;Gremese, Elisa;Papparella, Luigi Giovanni;Castri, Federica;Gasbarrini, Antonio;Armuzzi, Alessandro
2020
Abstract
Background: Mepolizumab (MEP) is the first anti Interleukin (IL)-5 add-on therapy approved for the treatment of severe refractory eosinophilic asthma. Case presentation: We describe here the case of a 49 years-old woman with Aspirin-exacerbated respiratory disease (AERD), chronic rhinosinusitis, nasal polyposis and eosinophilic gastroenteritis successfully treated with MEP. Several laboratory and clinical items improved during therapy; moreover MEP showed to be useful as steroid sparing agent. Conclusions: This case supports that the use of mepolizumab can be effective also in other eosinophilic conditions different from asthma and this opens to new therapeutic perspectives.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
